|
Diagnosis
|
Follow-up
|
Follow-up
|
---|
PC surface aberrant markers (SAM)
|
SAM expression (% of patients)
|
MRD-negative by cy-Ig light chains ratio on SAM percentage above the normal threshold 6, 7 (Putative surface MRD-positive) (% of samples)
|
MRD-positive by cy-Ig light chains ratio on SAM percentage below the normal threshold 6, 7 (Putative surface MRD-negative) (% of samples)
|
---|
CD19neg
|
98 %
|
CD19neg ≥30 %
|
2.5 %
|
CD19neg <30 %
|
26 %
|
CD45weak/neg
|
63 %
|
CD45weak/neg ≥6 %
|
38 %
|
CD45weak/neg <6 %
|
39 %
|
CD56pos
|
74 %
|
CD56pos ≥15 %
|
15 %
|
CD56pos <15 %
|
27 %
|
CD117pos
|
41 %
|
CD117pos ≥1 %
|
0 %
|
CD117pos <1 %
|
na
|
CD33pos
|
26 %
|
CD33pos ≥6 %
|
60 %
|
CD33pos <6 %
|
0 %
|
-
PC plasma cells, SAM surface aberrant marker, SAM% calculated within the CD38pos PC population, MRD minimal residual disease, cy-Ig cytoplasmic immunoglobulin, na not applicable